On 22 March, the Cybersecurity Administration of China (CAC) released the final version of a regulation governing the overseas transfer of personal, business and other data, including of health and medical data with implications for the biopharma industry.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?